These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 28236139)

  • 41. The mysteries of restless legs syndrome.
    Martin CM
    Consult Pharm; 2007 Nov; 22(11):907-24. PubMed ID: 18198978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome.
    Allen RP; Earley CJ; Jones BC; Unger EL
    Sleep Med; 2020 Jul; 71():141-148. PubMed ID: 32094092
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insight into the pathophysiology of restless legs syndrome.
    Earley CJ; Allen RP; Beard JL; Connor JR
    J Neurosci Res; 2000 Dec; 62(5):623-8. PubMed ID: 11104500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brain iron deficiency in idiopathic restless legs syndrome measured by quantitative magnetic susceptibility at 7 tesla.
    Li X; Allen RP; Earley CJ; Liu H; Cruz TE; Edden RAE; Barker PB; van Zijl PCM
    Sleep Med; 2016 Jun; 22():75-82. PubMed ID: 27544840
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis.
    Catoire H; Dion PA; Xiong L; Amari M; Gaudet R; Girard SL; Noreau A; Gaspar C; Turecki G; Montplaisir JY; Parker JA; Rouleau GA
    Ann Neurol; 2011 Jul; 70(1):170-5. PubMed ID: 21710629
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Restless legs syndrome and PD: a review of the evidence for a possible association.
    Garcia-Borreguero D; Odin P; Serrano C
    Neurology; 2003 Sep; 61(6 Suppl 3):S49-55. PubMed ID: 14504380
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Diagnosis and novel treatment approaches in restless legs syndrome: II. Treatment].
    Hirata K; Suzuki K
    Brain Nerve; 2013 Nov; 65(11):1391-9. PubMed ID: 24200617
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
    Hornyak M; Scholz H; Kohnen R; Bengel J; Kassubek J; Trenkwalder C
    Sleep Med Rev; 2014 Apr; 18(2):153-64. PubMed ID: 23746768
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Restless-legs syndrome].
    Karroum E; Konofal E; Arnulf I
    Rev Neurol (Paris); 2008; 164(8-9):701-21. PubMed ID: 18656214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopamine and the spinal cord in restless legs syndrome: does spinal cord physiology reveal a basis for augmentation?
    Paulus W; Schomburg ED
    Sleep Med Rev; 2006 Jun; 10(3):185-96. PubMed ID: 16762808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sensory symptoms in restless legs syndrome: the enigma of pain.
    Winkelman JW; Gagnon A; Clair AG
    Sleep Med; 2013 Oct; 14(10):934-42. PubMed ID: 23948222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Restless leg syndrome associated with atypical antipsychotics: current status, pathophysiology, and clinical implications.
    Aggarwal S; Dodd S; Berk M
    Curr Drug Saf; 2015; 10(2):98-105. PubMed ID: 24861990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Restless legs syndrome.
    Klingelhoefer L; Bhattacharya K; Reichmann H
    Clin Med (Lond); 2016 Aug; 16(4):379-82. PubMed ID: 27481386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of functional GLO1 variants in the BTBD9 locus and restless legs syndrome.
    Gan-Or Z; Zhou S; Ambalavanan A; Leblond CS; Xie P; Johnson A; Spiegelman D; Allen RP; Earley CJ; Desautels A; Montplaisir JY; Dion PA; Xiong L; Rouleau GA
    Sleep Med; 2015 Sep; 16(9):1151-5. PubMed ID: 26298793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mu opioid receptor knockout mouse: Phenotypes with implications on restless legs syndrome.
    Lyu S; DeAndrade MP; Unger EL; Mueller S; Oksche A; Walters AS; Li Y
    J Neurosci Res; 2020 Aug; 98(8):1532-1548. PubMed ID: 32424971
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endocrine rhythms in patients with restless legs syndrome.
    Wetter TC; Collado-Seidel V; Oertel H; Uhr M; Yassouridis A; Trenkwalder C
    J Neurol; 2002 Feb; 249(2):146-51. PubMed ID: 11985379
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome.
    Connor JR; Wang XS; Allen RP; Beard JL; Wiesinger JA; Felt BT; Earley CJ
    Brain; 2009 Sep; 132(Pt 9):2403-12. PubMed ID: 19467991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Idiopathic restless legs syndrome treatment: Progress and pitfalls?
    Ghorayeb I
    Adv Pharmacol; 2019; 84():207-235. PubMed ID: 31229172
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Possible sites of therapeutic action in restless legs syndrome: focus on dopamine and α2δ ligands.
    Thorpe AJ; Clair A; Hochman S; Clemens S
    Eur Neurol; 2011; 66(1):18-29. PubMed ID: 21709418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
    García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
    Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.